15th INTERNATIONAL CONGRESS OF PARKINSON'S

Abstracts by Topic
332 Hypomania and obsessive traits are lateralized in Parkinson’s disease
patients
S. Piacentini, R. Versaci, F. Ferré, L. Romito, A. Albanese (Milano, Italy)
333 Clinical features of dopamine agonist withdrawal syndrome (DAWS)
in a movement disorders clinic
M. Pondal, C. Marras, J.M. Miyasaki, E. Moro, M. Armstrong,
A.P. Strafella, B.B. Shah, S.H. Fox, L.K. Prashanth, N. Phielipp,
A.E. Lang (Toronto, Ontario, Canada)
334 Neuropsychiatric co-morbidities in non-demented patients with
Parkinson’s disease: A cross-sectional study
N.K. Rai, V. Goyal, N. Kumar, G. Shukla, S. Singh, M. Behari (New
Delhi, Delhi, India)
335 A novel way to measure speech intelligibility in individuals with
Parkinson’s disease
A. Halpern, J. Spielman, L. Ramig, I. Panzer, A. Sharpley, H. Gustafson
(Boulder, Colorado, USA)
336 Prefrontal dopaminergic changes associated with pathological
gambling in Parkinson’s disease
N.J. Ray, F. Antonelli, J.M. Miyasaki, J.H. Ko, M. Zurowski, A.E. Lang,
S. Houle, G. Pellecchia, A.P. Strafella (Toronto, Ontario, Canada)
337 Impulse-control disorders in Parkinson’s disease patients
S. Perez-Lloret, M.V. Rey, J.-L. Montastruc, O. Rascol (Toulouse,
France)
338 Parkinson’s disease patients affected with pathological gambling
show high interference in the Stroop task
R. Ribacoba, E. Herrera, S. González, E. Suárez, M. Menéndez-González
(Oviedo, Asturias, Spain)
339 Apathy in non-demented and non-depressed Parkinson’s disease
patients: A PET-study
G. Robert, F. Le Jeune, T. Dondaine, C. Lozachmeur, B. Millet,
M. Verin (Rennes, France)
340 Prevalence and determinants of depression in Mexican patients with
Parkinson’s disease
M. Rodríguez-Violante, A. Cervantes-Arriaga, C. Berlanga-Flores,
A. Ruiz-Chow, T. Corona (Mexico City, Mexico)
341
1H nuclear magnetic resonance spectroscopy findings in PD patients
with psychosis
M. Rodríguez-Violante, A. Cervantes-Arriaga, A. Villar-Velarde, C. De
la Fuente, T. Corona (Mexico City, Mexico)
342 Visual hallucinations in patients with Parkinson’s disease: Identifying
differences by gender and laterality of presenting symptoms
A. Sampat, N. Hermanowicz, S. Nguyen, M. Haske-Palomino (Irvine,
California, USA)
343 Non-motor fluctuations induced by levodopa administration in
Parkinson’s disease: A pilot study using profile of mood states scale
C. Siri, N. Meucci, A. Colombo, G. Sacilotto, M. Zini, G. Pezzoli
(Milan, Italy)
344 Dopaminergic replacement therapy enhances artistic productivity in
patients with Parkinson’s disease
P. Solla, A. Cannas, G. Floris, E. Costantino, G. Orofino, C. Serra,
M.G. Marrosu, F. Marrosu (Monserrato, Italy)
345 Dyskinetic Parkinson’s disease subjects off medication are excessively
responsive to extraneous visual input
J.K. Stevenson, P. Talebifard, E. Ty, M.M.K. Oishi, M.J. McKeown,
M. McKeown (Vancouver, Canada)
15 th INTERNATIONAL CONGRESS OF PARKINSON’S
DISEASE AND MOVEMENT DISORDERS
346 Electroconvulsive therapy in Parkinson’s disease with severe
psychosis
M. Takanashi, A. Nakajima, A. Yoritaka, N. Hattori (Bunkyo, Tokyo,
Japan)
347 Impulsive-compulsive behaviours in an Asian Parkinson’s disease
cohort
Z.-K. Tan, T.L. Lor, H. Mohamad, P.I. Ngam, J.P. Schee, A.K. Tan,
J.Y. Goh, E. Ooi, C.Y. Chow, S.L. Liew, S.-Y. Lim (Kuala Lumpur,
Selangor, Malaysia)
348 Impulse control disorders in Parkinson’s disease: A case control study
G. Valença, P. Glass, N. Negreiros, M. Duarte, L. Ventura, M. Mueller,
J. Oliveira-Filho (Salvador, Bahia, Brazil)
349 Punding prevalence in Parkinson’s disease
G. Valença, P. Glass, N. Negreiros, M. Duarte, L. Ventura, M. Mueller,
J. Oliveira-Filho (Salvador, Bahia, Brazil)
350 Spatiotemporal coordination deficits in Parkinson patients with
freezing of gait
S. Vercruysse, J. Spildooren, E. Heremans, J. Vandenbossche,
N. Wenderoth, S. Swinnen, W. Vandenberghe, A. Nieuwboer (Leuven,
Belgium)
351 Parkinson’s disease dysphonia: Results from 273 patients of the Aixen-Provence
parkinsonian speech database
S. Pinto, A. Ghio, B. Teston, F. Viallet (Aix-en-Provence Cedex 1,
France)
352 Behavioral prolife in Parkinson’s disease with impulse control
disorders. Before and after dopaminergic medication management
C. Villa, S. Martinez-Horta, B. Pascual-Sedano, C. Garcia-Sanchez,
J. Pagonabarraga, A. Campolongo, R. Fernandez, A. Gironell,
J. Kulisevsky (Barcelona, Spain)
353 The role of vision in Parkinson’s disease locomotion control:
Obstacle crossing task
R. Vitório, E. Lirani-Silva, F.A. Barbieri, V. Raile, F. Stella, L.T.B. Gobbi
(Americana, São Paulo, Brazil)
354 Impulse control disorders and punding in patients of Parkinson’s
disease in India
P.M. Wadia (Mumbai, Maharshtra, India)
Parkinson’s disease: Clinical Trials
355 Effects of forced exercise (FE) and levodopa therapy (LD) on motor
pathways in Parkinson’s disease (PD)
A. Ahmed, M.J. Phillips, J.L. Alberts (Cleveland, Ohio, USA)
356 Withdrawn by Author
357 A new concept in levodopa therapy: Microtablets and an electronic
dose-automat
S.-M. Aquilonius, C. Gomes-Trolin, T. Lewander, D. Nyholm,
C. Nyström (Uppsala, Sweden)
358 PET assessment of the aromatic L-amino acid decarboxylase gene
expression in a phase I gene therapy study for Parkinson’s disease
S. Asari, K. Fujimoto, S. Kato, H. Mizukami, K. Ikeguchi, T. Kawakami,
M. Urabe, E. Watanabe, T. Sato, K. Ozawa, I. Nakano, S. Muramatsu
(Shimotsuke, Tochigi, Japan)
359 Effects of multimodal exercise program on functional capacity in
people with Parkinson’s disease
R.A. Batistela, A.K.G. Prado, E. Lirani-Silva, F.A. Barbieri, R. Vitório,
P.C.R. Santos, L.C. Morais, L.T.B. Gobbi, PROPARKI Group (Rio
Claro, São Paulo, Brazil)
TORONTO
97
June 5–9, 2011 Toronto, ON, C anada
Abstracts
by topic